ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
复制标题
DOI：
10.1159/000225950
复制
发表时间：
2009-01-01
影响因子：
4.1
通讯作者：
Ploeckinger, Ursula
中科院分区：
文献类型：
--
作者：
Eriksson, Barbro;Annibale, Bruno;Ploeckinger, Ursula
神经内分泌肿瘤的化疗包括链脲佐菌素(STZ)+阿霉素和/或5-氟尿嘧啶(5-FU)、顺铂+依托泊苷和达卡巴秦的联合治疗。最近，一些新的化疗药物开始使用，如替莫唑胺、奥沙利铂和卡培他滨，但这里不再讨论这些药物。根据ENETS指南中规定的原发肿瘤定位、分期和增殖指数来决定是否进行化疗。应该强调的是，化疗可能会引发荷尔蒙危机。
Chemotherapy for neuroendocrine tumors includes treatment with combinations of streptozotocin (STZ)+ doxorubicin and/or 5-fluorouracil (5-FU), cisplatin+ etoposide and dacarbazine. Recently, some new chemotherapeutic agents have come into use, such as temozolomide, oxaliplatin, and capecitabine, but they will not be discussed here.The decision to give chemotherapy should be based on criteria of primary tumor localization, stage and proliferation index as stated in the ENETS Guidelines. It should be emphasized that administration of chemotherapy may elicit hormonal crises.